MADRIGAL PHARMACEUTICALS, INC.

Madrigal Pharmaceuticals, Inc. announced it granted equity inducement awards to seven new non-executive employees on July 1, 2026. These awards, approved by the independent Compensation Committee, included options to purchase 604 shares of common stock and 2,952 time-based restricted stock units. The options have an exercise price of $514.39 per share, and both options and RSUs are subject to multi-year vesting schedules contingent on continued employment.

Madrigal Pharmaceuticals granted 1,397 time-based restricted stock units (RSUs) to five new non-executive employees on June 15, 2026. These equity inducement awards, approved by the independent Compensation Committee, vest in four equal annual installments, subject to continued employment. The awards were a material inducement for the employees to accept their positions at the biopharmaceutical company, which focuses on MASH treatments.

Madrigal Pharmaceuticals' stockholders approved the 2026 Stock Plan and the 2026 Employee Stock Purchase Plan at the Annual Meeting on June 17, 2026. Additionally, the Board of Directors adopted a new Nonqualified Deferred Compensation Plan on June 16, 2026, effective August 1, 2026, for key management and non-employee directors. This plan allows pre-tax deferrals of salary, bonuses, fees, and equity. Separately, Dr. Rebecca Taub will transition from an employee to a consultant, providing scientific and medical guidance for the company's MASH programs, effective July 1, 2026.

Madrigal Pharmaceuticals granted 6,881 time-based restricted stock units (RSUs) to 20 new non-executive employees on June 1, 2026. These equity inducement awards were approved by the independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4) to incentivize employees' acceptance of employment. The RSUs will vest in four equal installments over four years, contingent on continued employment.

Madrigal Pharmaceuticals, Inc. announced it granted 5,308 time-based restricted stock units (RSUs) to 15 new non-executive employees on May 15, 2026. These equity inducement awards were approved by the company's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs are designed to vest in four equal installments on each of the first through fourth anniversaries of the grant date, subject to the employees' continued employment.

Madrigal Pharmaceuticals reported a significant increase in product revenue for Q1 2026, reaching $311.3 million, a 126.8% increase year-over-year, driven by the commercialization of Rezdiffra. The company's net loss widened to $94.4 million, or $(3.25) per share, compared to a net loss of $73.2 million, or $(2.61) per share, in Q1 2025, primarily due to increased operating expenses for research and development and selling, general, and administrative activities. Madrigal continues to commercialize Rezdiffra in the U.S. and Germany and is evaluating it for a broader MASH patient population.

Madrigal Pharmaceuticals reported strong first-quarter 2026 financial results, with Rezdiffra net sales reaching $311.3 million, a 127% increase year-over-year. The company also announced a global licensing agreement for a clinical-stage siRNA asset targeting a PNPLA3 gene mutation, expanding its MASH pipeline. As of March 31, 2026, over 42,250 patients were on Rezdiffra, reflecting continued strong demand. Despite increased operating expenses due to commercial investments and business development, the company maintains a strong cash position of $817.9 million.

Madrigal Pharmaceuticals reported strong first-quarter 2026 financial results, with Rezdiffra net sales reaching $311.3 million, a 127% year-over-year increase. The company also saw significant patient adoption, with over 42,250 patients on Rezdiffra, a 2.5x increase from Q1 2025. Madrigal strengthened its pipeline by licensing a clinical-stage siRNA asset targeting a PNPLA3 gene mutation for MASH and reported $817.9 million in cash and equivalents.

Madrigal Pharmaceuticals' Board of Directors reclassified the membership of its three director classes on April 22, 2026, to achieve a more equal apportionment. Julian C. Baker and Daniel J. Brennan were reclassified as Class I directors, effective immediately. This procedural change did not interrupt their service or alter their committee assignments, and they are nominated for re-election at the upcoming 2026 Annual Meeting.

Madrigal Pharmaceuticals reported strong performance for Rezdiffra in 2025, achieving $958.4 million in net sales and exiting the year with quarterly revenue annualizing over $1 billion. The company established Rezdiffra as the foundational therapy in MASH, with over 36,250 patients on therapy and patent protection extended to 2045. Madrigal also expanded its pipeline to over ten programs and will hold its Annual Meeting on June 17, 2026, to vote on director elections and new stock plans.